Various Methods of Laser Photobiomodulation Therapy for Alzheimer's Disease
Main Article Content
Abstract
Alzheimer's disease is the most common neurodegenerative disease. It is believed that the number of people suffering from Alzheimer's disease worldwide is about 32 million, and the number of people with the preclinical stage of the disease can be up to 300 million.
For a long time, it was believed that Alzheimer's disease arises as a result of disorders in the metabolism of amyloid beta and tau-protein in cerebral tissue. According to numerous recent studies, it has been established that the disease is accompanied by dyscirculatory angiopathy of Alzheimer's type. This is an Alzheimer's disease-specific complex lesion of the cerebral vascular system with arterial, microcirculatory, and venous bed disorders.
One of the most promising directions in the field of brain revascularization, as well as the regeneration of cerebral tissue in Alzheimer's disease, is the use of laser with low output power. This direction was named laser “photobiomodulation therapy”.
Currently, laser photobiomodulation therapy is divided into transcranial, intranasal, intravascular (intravenous) and transcatheter intracerebral methods of treatment.
Laser energy has a complex effect on cerebral tissues. Photobiomodulation therapy stimulates angiogenesis, causes collateral and capillary revascularization, restores the exchange of adenosine triphosphate in neuronal mitochondria, improves cellular and tissue metabolism, stimulates neurogenesis, and causes regeneration of tissue structures.
Various types of Photobiomodulation therapy are non-traumatic, physiological, pathogenetically substantiated, effective methods for the treatment of cerebral microcirculatory disorders in Alzheimer's disease. The choice of one or another method of laser photobiomodulation therapy is purely individual and depends on the specific clinical case.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Van der Flier WM, De Vugt ME, Smets EMA, Blom M, Teunissen ChE. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nature Aging. 2023; (3): 494-505. DOI: 10.1038/s43587-023-00404-2
3. Morel F. An apparently dyshoric and topical angiopathy. Monatsschr Psychiat Neurol. 1950; 120, 5-6: 352-357.
4. Maksimovich I V. Method for Endovascular Treatment of Alzheimer’s Disease. 2006. Patent, No.2297860 Russian.
5. Maksimovich I V. Method and Device for Endovascular Treatment of Alzheimer’s Disease. 2008. Patent No. 7389776.USA.
6. Maksimovich IV. Dyscirculatory Angiopathy of Alzheimer’s Type. Journal of Behavioral and Brain Science. 2011; 1 (2): 57-68. DOI: 10.4236/jbbs.2011.12008
7. Maksimovich IV. Cerebrovascular Changes and Cerebral Atrophy in the Development of Dementia during Alzheimer's Disease. Medical Research Archives. 2023; 11 (5): 1-10. https://doi.org/10.18103/mra.v11i5.3869
8. Cai Z, Wang C, He W, Tu H, Tang Z, Xiao M, Yan L. 2015. Cerebral small vessel disease and Alzheimer's disease. Clin Interv Aging. 2015; 23, (10): 1695-1704. https://doi.org/10.2147/CIA.S90871
9. Rafii MS, Aisen PS Detection and treatment of Alzheimer’s disease in its preclinical stage. Nature Aging. 2023; 3: 520-531. DOI: 10.1038/s43587-023-00410-4
10. Maksimovich IV and Polyaev YuA. The Importance of Early Diagnosis of Dyscircular Angiopathy of Alzheimer's Type in the Study of Heredity of Alzheimer's Disease. Journal of Alzheimer’s & Dementia. 2010; 6, 4S, (21): 43-45. https://doi.org/10.1016/j.jalz.2010.08.133
11. Yang AC , Vest RT , Kern F , Lee DP et al. A human brain vascular atlas reveals diverse mediators of Alzheimer's risk. Nature. 2022;603,(7903):885-892. DOI: 10.1038/s41586-021-04369-3
12. Sun N, Akay LA, Murdoc MH, Park Y et al. Single-nucleus multiregion transcriptomic analysis of brain vasculature in Alzheimer’s disease. Nature Neuroscience. 2023; 26: 970-982 DOI: 10.1038/s41593-023-01334-3
13. Baloiannis SJ and Baloiannis IS. The vascular factor in Alzheimer’s disease: A study in Golgi technique and electron microscopy. Journal of the Neurological Sciences 2012; 322: 117-121. https://doi.org/10.1016/j.jns.2012.07.010
14. Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochim Biophys Acta. 2016; 1862, (5): 887-900. https://doi.org/10.1016/j.bbadis.2015.12.016
15. Baloyannis, S.J. Brain capillaries in Alzheimer's disease. Hell J Nucl Med 2015; 18, Suppl 1 :152. DOI: 10.15406/jnsk.2015.02.00069
17. Kimbrough, I.F., Robel, S., Roberson, E.D., Sontheimer, H. Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain. 2015; 138, (12): 3716-3733. https://doi.org/10.1093/brain/awv327
18. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropatho 2010; 120 (3): 287-396. doi: 10.1007/s00401-010-0718-6.
19. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med 2010; 16 (12): 1370-1371. doi: 10.1038/nm1210-1370
20. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews. Neuroscience. 2011; 12, 723-738. doi: 10.1038/nrn3114
21. Brenowitz WD, Hubbard RA, Keene CD, Hawes CE. Mixed neuropathologies and estimated rates of clinical progression in a large autopsysample. Alzheimers & Dementia. 2017;13(6):654-662 doi: 10.1016/j.jalz.2016.09.015
22. Bell RD & Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathologica 2009; 118: 103-113. doi: 10.1007/s00401-009-0522-3
23. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV,. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85, (2): 296-302. http://dx.doi.org/10.1016/j.neuron.2014.12.032
24. Maksimovich IV. Certain new aspects of etiology and pathogenesis of Alzheimer’s disease. Advances in Alzheimer’s Disease, 2012; 1, (3): 68-76. DOI: 10.4236/aad.2012.13009
25. De la Torre JC. Cerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia. Brain Pathology 2016; 26, (5): 618–631 https://doi.org/10.1111/bpa.12405
26. Hashmi JT, Huang YY, Osmani BZ, Sharma SK, Naeser MA and Hamblin MR. Role of low-level laser therapy in neurorehabilitation. Arch Phys Med Rehab. 2010; 12 (2): S 292–305. https://doi.org/10.1016/j.pmrj.2010.10.013
27. Naeser MA, Hamblin MR. Potential for transcraniallaser or LED therapy to treatstroke, traumatic brain injury, and neurodegenerative disease. Photomed Laser Surg. 2011; 29 (7): 443-446. https://doi.org/10.1089/pho.2011.9908
28. Hamblin MR. Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned? Photonics. 2019; 6 (3), 77. https://doi.org/10.3390/photonics6030077
29. Hamblin MR. Mechanisms of photobiomodulation in the brain. In Photobiomodulation in the Brain, Edited by Michael R. Hamblin, Ying-Ying Huang. Academic Press is an imprint of Elsevier, London. 2019; p-p. 97-110. https://doi.org/10.1016/B978-0-12-815305-5.00008-7
30. Maksimovich IV. Transcatheter intracerebral photobiomodulation in degenerative brain disorders: clinical studies (Part 1). In Photobiomodulation in the Brain, Edited by Michael R. Hamblin, Ying-Ying Huang. Academic Press is an imprint of Elsevier, London, 2019; p-p. 515-528. https://doi.org/10.1016/B978-0-12-815305-5.00038-5
31. Mester E, Szende B, Gartner P. The effect of laser beams on the growth of hair in mice. Radiobiol Radiother (Berl) 1968; 9:621–626.
32. Deviatkov ND. Application of electronics in medicine and biology. Electronic Equipment: Microwave Equipment 1993; 1:66-76.
33. Maksimovich I. V. Transluminal laser angioplasty in the treatment of ischemic brain lesions. Doctoral Dissertation, RUDN University: Peoples' Friendship University of Russia, Moscow, 2004.
34. Salehpour F, Hamblin MR, Di Duro JO. Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report. Photobiomodul Photomed Laser Surg 2019; 37 (3): 159-167. DOI: 10.1089/photob.2018.4569
35. Ming-Wei Lai, Chia-Hsin Yang, Pi-Yu Sung, and Sen-Wei Tsai. Intravascular Laser Irradiation of Blood Improves Functional Independence in Subacute Post-Stroke Patients: A Retrospective Observational Study from a Post-Stroke Acute Care Center in Taiwan. Photobiomodulation, Photomedicine, and Laser Surgery. 2022; 40, (10): 691–697. https://doi.org/10.1089/photob.2022.0042
36. Maksimovich IV. Intracerebral Transcatheter Laser PBMT in the Treatment of Binswanger's Disease and Vascular Parkinsonism: Research and Clinical Experience. Photobiomodul Photomed and Laser Surg. 2019; 37, 10: 606-614. https://doi.org/10.1089/photob.2019.4649
37. Maksimovich IV. Study of the Impact of Transcatheter Intracerebral Laser Photobiomodulation Therapy Treatment on Patients with Alzheimer's Disease and Binswanger's Disease. Medical Research Archives 2022; 10, (12): 1-13. https://doi.org/10.18103/mra.v10i12.3420
38. Maksimovich IV. Transcatheter intracerebral photobiomodulation in ischemic brain disorders: clinical studies (Part 2). Photobiomodulation in the Brain. Edited by Michael R. Hamblin, Ying-Ying Huang, Academic Press is an imprint of Elsevier, London 2019; 529-544. https://doi.org/10.1016/B978-0-12-815305-5.00039-7